Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Thomas Crawford, MD

Healthcare Professional
Muscular Dystrophy Association Clinic
Johns Hopkins Pediatrics
200 N. Wolfe Street
Rubenstein Child Health Building, Suite 2158
Baltimore, Maryland, United States

Dr. Tom Crawford has been a member of the Department of Neurology since 1987. He is the Co-Director of the MDA Clinic for Neuromuscular Disorders and Neurologist for the Ataxia Telangiectasia Clinical Center at Johns Hopkins. His practice involves general child neurology with a principal interest in caring for children with neuromuscular, neuromotor, and ataxic disorders. Primary research interests involve the basic science and clinical characterization of two important neurologic disorders that affect children: Spinal Muscular Atrophy and Ataxia Telangiectasia.

Dr. Tom Crawford is also actively involved in the Biology of neurofilaments by characterization of transgenic animal models. He is on the Medical and Scientific Advisory Boards of Families of Spinal Muscular Atrophy, and the Medical Advisory Committee for the Muscular Dystrophy Association. Dr. Crawford is the Neurologist for the Ataxia Telangiectasia Clinical Center at Johns Hopkins, which has evaluated almost half of the known patients with this disorder in the United States. Additional specific clinical interests include evaluation and treatment of children with brachial plexus palsies.

Dr. Tom Crawford has published extensively and presented nationally and internationally. He has an active role in teaching medical students and residents in neurology. In addition, Dr. Crawford has special interest and experience in EMG studies of children and adults.


Representative Publications:

Safety and Efficacy of Nusinersen in Spinal Muscular Atrophy: The EMBRACE Study

Revised Recommendations for the Treatment of Infants Diagnosed With Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2

Neurofilament As a Potential Biomarker for Spinal Muscular Atrophy

Treatment Algorithm for Infants Diagnosed With Spinal Muscular Atrophy Through Newborn Screening

Two Breakthrough Gene-Targeted Treatments for Spinal Muscular Atrophy: Challenges Remain


Related Content